Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Serina Therapeutics (SER) Income from Non-Controlling Interests (2018 - 2025)

Serina Therapeutics (SER) has disclosed Income from Non-Controlling Interests for 8 consecutive years, with -$10000.0 as the latest value for Q3 2025.

  • Quarterly Income from Non-Controlling Interests rose 62.96% to -$10000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$33000.0 through Dec 2025, up 50.0% year-over-year, with the annual reading at -$33000.0 for FY2025, 50.0% up from the prior year.
  • Income from Non-Controlling Interests hit -$10000.0 in Q3 2025 for Serina Therapeutics, up from -$14000.0 in the prior quarter.
  • In the past five years, Income from Non-Controlling Interests ranged from a high of -$1000.0 in Q1 2022 to a low of -$58000.0 in Q4 2022.
  • Historically, Income from Non-Controlling Interests has averaged -$15333.3 across 5 years, with a median of -$10000.0 in 2023.
  • Biggest five-year swings in Income from Non-Controlling Interests: surged 85.71% in 2022 and later plummeted 700.0% in 2023.
  • Year by year, Income from Non-Controlling Interests stood at -$7000.0 in 2021, then tumbled by 728.57% to -$58000.0 in 2022, then surged by 82.76% to -$10000.0 in 2023, then fell by 20.0% to -$12000.0 in 2024, then rose by 16.67% to -$10000.0 in 2025.
  • Business Quant data shows Income from Non-Controlling Interests for SER at -$10000.0 in Q3 2025, -$14000.0 in Q2 2025, and -$9000.0 in Q1 2025.